Ravicher attacks Myriad over BRCA patents
23 September 2010
Eileen McDermott, Washington DC
Dan Ravicher of the Public Patent Foundation this week claimed his actions “help the patent system maintain credibility for society” in a debate over his pending patent dispute with Myriad Genetics
Ravicher and the American Civil Liberties Union (ACLU) are representing a number of breast cancer and women's health groups, individual women, geneticists and scientific associations in a suit against Myriad.
The suit alleges that some claims of Myriad's seven patents on the BRCA1 and BRCA2 genes are invalid.
A US district court in late March agreed and invalidated the Myriad patents, in part based on the Federal Circuit's ruling in In re Bilski. The case is now on appeal to the Federal Circuit. But Ravicher said that the case is not about taking down gene patents altogether.
Ravicher spoke on Monday in Washington DC on a panel with Hans Sauer of the Biotechnology Industry Organization (BIO) and professor Scott Kieff held...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial